Chromatin activity of I?Ba mediates the exit from naive pluripotency


Por: Palma, LG, Alvarez-Villanueva, D, Maqueda, M, Barrero, M, Iglesias, A, Bertran, J, Alvarez, D, Garcia-Prieto, CA, Ballare, C, Rodriguez-Cortez, V, Bueno, C, Vidal, A, Villanueva, A, Menendez, P, Stik, G, Di Croce, L, Payer, B, Esteller, M, Espinosa, L and Bigas, A

Publicada: 22 oct 2025 Ahead of Print: 22 oct 2025
Resumen:
Maintenance of pluripotency is a multifactorial process in which NF-kappa B is a negative regulator. Our previous work identified a chromatin role for I kappa B alpha, the master regulator of NF-kappa B signaling, that is critical for the proper regulation of various tissue stem cells. Here, we found that I kappa B alpha accumulates specifically in the chromatin fraction of mouse pluripotent stem cells. I kappa B alpha depletion does not affect NF-kB-dependent transcription, but causes a profound epigenetic rewiring in pluripotent stem cells, including alterations in H3K27me3, a histone mark catalyzed by Polycomb repression complex 2. Chromatin changes induced by I kappa B alpha depletion affect a subset of pluripotency genes and are associated with altered gene transcription. At the cellular level, I kappa B alpha-deficient embryonic stem cells are arrested in a naive pluripotency state when cultured in serum/LIF conditions and fail to exit pluripotency under differentiation conditions. By constructing separation-of-function mutants, we show that the effects of I kappa B alpha in regulating stem cell pluripotency are NF-kappa B-independent, but mainly rely on its chromatin-related function. Taken together, our results reveal a novel mechanism by which I kappa B alpha participates in the regulation of the pluripotent state of mouse embryonic stem cells and shed light on the interplay between inflammatory signals and the regulation of pluripotency.

Filiaciones:
Palma, LG:
 Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Alvarez-Villanueva, D:
 Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain

 Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain

Maqueda, M:
 Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Barrero, M:
 Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain

Iglesias, A:
 Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Bertran, J:
 Univ Vic, Univ Cent Catalunya, Vic, Spain

Alvarez, D:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Garcia-Prieto, CA:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Ballare, C:
 Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain

Rodriguez-Cortez, V:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Vidal, A:
 Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain

Villanueva, A:
 Catalan Inst Oncol ICO IDIBELL, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Carlos III Hlth Inst ISCIII, Spanish Network Adv Therapies RICORS TERAV, Madrid, Spain

 Univ Barcelona, Dept Biomed, Barcelona, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Di Croce, L:
 Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

 Univ Pompeu Fabra, Barcelona, Spain

Payer, B:
 Barcelona Inst Sci & Technol, Ctr Genom Regulationlat CRG, Barcelona, Spain

 Univ Pompeu Fabra, Barcelona, Spain

:
 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain

 Univ Barcelona UB, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain

Espinosa, L:
 Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

Bigas, A:
 Hosp Del Mar Res Inst, Program Canc Res, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
ISSN: 2050084X





eLife
Editorial
eLife Sciences Publications, SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 14 Número:
Páginas:
WOS Id: 001598876100001
ID de PubMed: 41123589
imagen Green Submitted, gold

MÉTRICAS